Supriya Lifescience Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹265 - ₹274
- Lot size
- 54 shares
- Issue amount
- ₹700 cr
- Total subscription
- 0×
- Opens
- 16 Dec 2021
- Closes
- 20 Dec 2021
- Allotment
- 23 Dec 2021
- Listing
- 28 Dec 2021
Offer at a glance
Issue overview
- Issue size
- 2,55,47,445 shares
- Face value
- ₹2 Per Share
- Minimum investment
- ₹14,310
- Fresh issue
- ₹200 cr
- Offer for sale
- ₹500 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,796
- Issue type
- Bookbuilding IPO
- Shares before issue
- 7,31,83,530
- Shares after issue
- 2,55,47,445
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 54 | ₹14,796 |
| sHNI | 14 | 756 | ₹2,07,144 |
| bHNI | 68 | 3,672 | ₹10,06,128 |
Share reservation
Subscription & GMP
Subscription by category
Subscription figures are awaiting publication.
GMP history
Financial performance
Company financials
in Lakhs · Reported periods may include interim results.
Company information
Company profile
Supriya Lifescience is a manufacturer of Active Pharmaceutical Ingredients (APIs), producing 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics. Between FY 2017 and FY 2021, it was the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, and one of the largest exporters of Salbutamol Sulphate in FY 2021. The company exports to 86 countries, serving 1,296 customers, including 346 distributors, across Europe, Latin America, Asia, and North America. Its modern manufacturing facility in Maharashtra spans 23,806 sq. m with a reactor capacity of 547 KL/day and seven clean rooms. Supriya Lifescience has acquired an additional 12,551 sq. m plot for expansion and holds regulatory approvals from USFDA, EDQM, TGA-Australia, KFDA-Korea, PMDA-Japan, NMPA-China, and Health Canada for its API exports.
Promoters
Satish Waman Wagh
Registrar & documents
Lead manager
ICICI Securities Limited, Axis Capital Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
207/208, Udyog Bhavan, Sonawala Road, Goregaon, East, Mumbai – 400063, Maharashtra, India
+91-22-40332727
Supriya Lifescience LimitedCompany website ↗Frequently Asked Questions
What is Supriya Lifescience IPO GMP today?
As of today, Supriya Lifescience IPO Grey Market Premium (GMP) is reported at +₹130 per share. Based on the upper price band of ₹274, the estimated listing price is ₹404 (+47.4% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Supriya Lifescience IPO?
The minimum bid lot size for Supriya Lifescience IPO is 54 shares. At the cut-off price of ₹274 per share, retail investors need a minimum application amount of ₹14,796 per lot. Retail applicants can apply for a maximum of 13 lots (up to ₹2,00,000).
When will Supriya Lifescience IPO allotment status be announced?
The allotment status for Supriya Lifescience IPO is scheduled to be finalized on 23 Dec 2021. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Link Intime India Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Supriya Lifescience IPO allotment status online by PAN?
To check Supriya Lifescience IPO allotment status: 1) Visit the registrar portal (Link Intime India Private Limited) or the BSE IPO allotment page. 2) Select 'Supriya Lifescience Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.